StreetAlpha
13F holdings · Q3 2026

Soleus Capital Management

Greenwich, CT · files as Soleus Capital Management, L.P.
Know the moment Soleus Capital Management filesYou follow Soleus Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1802630

Soleus Capital Management reported 97 stocks worth $2.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KRYS (13.5%), PODD (8.0%) and NVCR (5.3%). Compared with Q2 2026, the fund opened new positions in ZLAB, KOD and INBX, added to KRYS, PODD and UTHR, trimmed NVCR, TGTX and CELC and sold out of GMED, SUPN and LIVN.

Latest filing: what Soleus Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
27 new28 added36 trimmed27 sold outBought about $676M · sold about $617M
New 27
See all 27 →
Added 28
See all 28 →
Trimmed 36
See all 36 →
Sold out 27
See all 27 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$2.8B−3.1% vs last quarter
Stocks held9727 new · 27 sold out
Top 5 weight36.9%fairly concentrated
Turnover46%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
KRYS
Krystal Biotech Inc
$379M13.5%1.1M+200K (+21%)8 of 8
2
PODD
Insulet Corp
$225M8.0%1.7M+678K (+65%)4 of 8
3
NVCR
Novocure Ltd
$150M5.3%9.4M−488K (−5%)8 of 8
4
TGTX
TG Therapeutics Inc
$143M5.1%2.6M−372K (−13%)8 of 8
5
UTHR
United Therapeutics Corp Del
$140M5.0%259K+33K (+15%)8 of 8
6
CELC
Celcuity Inc
$134M4.8%1.7M−22K (−1%)8 of 8
7
RIGL
Rigel Pharmaceuticals Inc
$88.8M3.2%1.8MNo change8 of 8
8
INSP
Inspire Med Sys Inc
$83.7M3.0%1.2M−725K (−38%)7 of 8
9
ERAS
Erasca Inc
$74.9M2.7%5.1M+2.4M (+89%)7 of 8
10
BBNX
Beta Bionics Inc
$71.1M2.5%3.7M−650K (−15%)7 of 8
🔒 87 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GMED
Globus Med Inc
$37M469K
SUPN
Supernus Pharmaceuticals Inc
$24.2M520K
LIVN
Livanova PLC
$21M255K
SYRE
Spyre Therapeutics Inc
$13.1M147K
ALNY
Alnylam Pharmaceuticals Inc
$9.9M33K

🔒 Free account: see all 27.

Reported value

last 8 quarters
$1.3BQ4 '24
$1.3BQ1 '25
$1.4BQ2 '25
$1.9BQ3 '25
$2.4BQ4 '25
$2.5BQ1 '26
$2.9BQ2 '26
$2.8BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Soleus Capital Management 13F FAQ

What does Soleus Capital Management own?

Soleus Capital Management reported 97 stocks worth $2.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KRYS (13.5%), PODD (8.0%) and NVCR (5.3%). The table above lists every position in the filing (the top 10 without an account).

What did Soleus Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 27 new positions, 28 added to, 36 trimmed and 27 sold out. New positions include ZLAB, KOD and INBX. It sold all of GMED, SUPN and LIVN.

When will Soleus Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Soleus Capital Management's portfolio worth?

The Q3 2026 filing reports $2.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.